Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 470Unknown 90Active not recruiting 85Terminated 73Recruiting 47Withdrawn 20Not yet recruiting 4Enrolling by invitation 4Suspended 3

Sponsor Class

OTHER 309INDUSTRY 62OTHER_GOV 12NETWORK 5NIH 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 7Thoracic 5Lymphoid 4Plasma cell 3Genitourinary 3Gastrointestinal 3Sarcoma 2Gynecologic 2CNS 2Breast 2Myeloid 1Head & Neck 1Dermatologic 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Ann Arbor Stage II Mantle Cell Lymphoma 1

Interventions

Cyclophosphamide 3fludarabine 2Specimen Handling 2Magnetic Resonance Spectroscopy 2prednylidene 1glofitamab 1dexamethasone acetate 1dexamethasone 21-phosphate 1deltacortene 1auricularum 1Whole-Body Irradiation 1Vincristine 1Tacrolimus 1Rituximab 1Prednisone 1Platinum 1Mycophenolic Acid 1Doxorubicin 1Dexamethasone 1Cytarabine 1Cisplatin 1Calcium Dobesilate 1CT-P10 1Busulfan 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × NIH × Lymphoid × Clear all
NCT07524530 2026-06-05

Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Not yet recruiting
98 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Hematologic Neoplasms

NCT07572136 2026-06-05

Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)

National Institutes of Health Clinical Center (CC)

Phase 1 Not yet recruiting
57 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07332507 2026-05-13

Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
30 enrolled
Lymphoid

Plasmablastic Lymphoma

NCT07444710 2026-05-13

Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
16 enrolled
Lymphoid

Ann Arbor Stage II Mantle Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡